AstraZeneca Rises 2.5% on Report CEO Wants to Move Listing to US

Bloomberg
07-01

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s stock listing to the US, in what would be a major blow to the UK’s equity markets.

U.S.-listed shares of AstraZeneca rose 2.5% on Tuesday.

Soriot has also discussed moving AstraZeneca’s domicile, the Times said, citing people familiar with the matter it didn’t identify. The executive is frustrated with the UK’s regulatory regime for drugs and is concerned the country is falling behind the US and China, it said.

“We do not comment on speculation,” AstraZeneca spokesman Tony Ho Wan Loke said by email.

AstraZeneca shares rose as much as 3.2% in London after the report, almost erasing their year-to-date decline. With a market value of about £160 billion ($220 billion), the drugmaker is Britain’s largest publicly traded company.

A series of companies have moved their primary stock listing from London to the US in recent years often in search of improved liquidity. International payments firm Wise Plc is the latest company to weigh such a move, saying last month that it will consult shareholders on the matter.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10